THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

: 1642

Serial No.

: K. Canella : 09/503,089

Filed

Title

: February 11, 2000

Inventors

: Amanda J. Patel

: Eric Honore : Florian LeSage : Georges Romey

: Michel Lazdunski : A METHOD FOR THE

: IDENTIFICATION OF

: ANESTHETICS

FEB 0 4 2002

PATENT TRADEMARK OFFICE

TECH CENTER 1600/2900

Docket No.: 1201-CIP-3-00

Dated: December 27, 2001

Commissioner for Patents Washington, DC 20231

Sir:

Certificate of Mailing Under 37 CFR 1.8

For


Postcard \$126.00 Check Amendment Transmittal Letter, in duplicate Response

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231, on the date appearing below.

> Name of Applicant, Assignee, Applicant's Attorney or Registered Representative:

> > Schnader Harrison Segal & Lewis Customer No. 022469

Ву: _					
Date:	27 DEC 2001				



Attorney Docket No.: 1201-CIP3-00

RECEIVED

Serial No.: 09/503,089

FEB 0 4 2002

Filed:

February 11, 2000

TECH CENTER 1600/2800

For:

A METHOD FOR THE IDENTIFICATION OF ANESTHETICS

COMMISSIONER FOR PATENTS

Washington, DC 20231

Sir:

Transmitted herewith is an Amendment in the above-identified application.

- Small entity status of this application under 37 CFR §1.9 and §1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR §1.9 and §1.27 is enclosed.
- No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)

(Col. 2) (Col. 3)

SMALL ENTITY

OTHER THAN **SMALL ENTITY**

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PRE- VIOUSLY PAID FOR	PRESENT EXTRA		
TOTAL	* 25		** 21 =	0		
INDEP.	* 8	-	***11 =	3		
First presentation of multiple dependent claim						

RATE	ADD'L FEE
x 9=	\$
x42=	\$126.00
+140=	\$

RATE	ADD'L FEE
x18=	\$
x84=	\$
+280=	\$

TOTAL ADDITIONAL FEE

\$126.00

OR

OR

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3. If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- Please charge my Deposit Account No. 13-3405 in the amount of \$_____. A duplicate copy of this sheet is enclosed.
- A check in the amount of \$126.00 is attached.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 13-3405. A duplicate copy of this sheet is enclosed.
 - x Any filing fees under 37 CFR §1.16 for the presentation of extra claims.
 - Any patent application processing fees under 37 CFR §1.17 with the exception of the Issue Fee which we intend to pay by check.

T. Daniel Christenbury

Reg. No. 31,750

Attorney for Applicant(s)

TDC:dh (215)563-1810

11/A 2.22.02

N THE UNITED STATES PATENT AND TRADEMARK OFFICE.

(: 16

: 1642

: K. Canella : 09/503,089

Serial No. Filed Inventors

February 11, 2000

Amanda J. Patel Eric Honore

Florian LeSage Georges Romey

Michel Lazdunski

Title

A METHOD FOR THE IDENTIFICATION OF

ANESTHETICS

22469

PATENT TRADEMARK OFFICE

RECEIVED

FEB 0 4 2002

TECH CENTER 1600/2900

Docket No.: 1201-CIP-3-00

Dated: December 27, 2001

RESPONSE

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Official Action dated September 27, 2001, Applicants amend as follows:

Marked-Up Version Showing Changes Made to the Specification

Page 6, third full paragraph:

The cells expressing the potassium transport protein may transiently express the protein or constitutively express the protein. The cells may be of any type which can express the protein in appropriate conformation to allow for the transport of potassium. Examples of such cells include, mammalian cells, vertebrate cells, and invertebrate cells. Examples of mammalian cells suitable for use in the invention include, but are not limited to, cells of neuronal origin, fibroblasts, myocardial cells, COS cells, Chinese hamster ovary (CHO) cells, embryonic kidney cells, fibroblasts, HELAHeLa cells, and the like. Examples of suitable non-mammalian vertebrate cells include, but are not limited to frog oocytes, such as Xenopus laevis oocytes, and the like. Suitable invertebrate cells include, but are not limited to insect cells, such as Spodoptera frugiperda (Sf9) cells, and the like. Any cell known in the art which may be transfected to transiently or constitutively express the